Encyclopedia of Behavioral Medicine

2013 Edition
| Editors: Marc D. Gellman, J. Rick Turner

Insulin Pumps

  • Della Matheson
Reference work entry
DOI: https://doi.org/10.1007/978-1-4419-1005-9_1198



Insulin pump therapy, often referred to as continuous subcutaneous insulin infusion (CSII), is an alternate method of insulin administration for persons who require multiple daily injections (MDI) for treatment of diabetes. The concept in insulin pump therapy was first introduced by Arnold Kadish in Beverly Hills, CA, in the 1960s. However, it was not until the early 1980s that the first FDA-approved pump became available for use by people with type 1 diabetes.

The basic design of pumps is that a syringe-driven pump uses a subcutaneously placed catheter to deliver insulin that is controlled by electronics within the pump (Skyler, 2010). The insulin used in pumps is rapid-acting insulin (regular insulin or more recently the insulin analogs: Novolog, Humalog, Apidra). Insulin pumps provide the most physiologic method for delivery of insulin. In nondiabetic people, the pancreas secretes background insulin throughout the day...

This is a preview of subscription content, log in to check access.

References and Readings

  1. Ponder, S. W., Skyler, J. S., Kruger, D. F., Matheson, D., & Brown, B. W. (2008). Unexplained hyperglycemia in continuous subcutaneous insulin infusion: Evaluation and treatment. The Diabetes Educator, 34, 327–333.PubMedCrossRefGoogle Scholar
  2. Skyler, J. S. (2010). Continuous subcutaneous insulin infusion – An historical perspective. Diabetes Technology & Therapeutics, 12(Suppl. 1), S5–S7.Google Scholar
  3. Skyler, J. S., Ponder, S. W., Kruger, D. F., Matheson, D., & Parkin, C. G. (2007). Is there a place for insulin pump therapy in your practice? Clinical Diabetes, 2, 50–56.CrossRefGoogle Scholar
  4. The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine, 329, 977–986.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2013

Authors and Affiliations

  1. 1.Diabetes Research Institute, Miller School of MedicineUniversity of MiamiMiamiUSA